SURVYR

OCS

Oculis Holding AG
$7.83
−$0.13 (1.63%)Oct 27 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-67%-35%-4%+28%+60%Oct 2025Oct 2026Apr 202652w high $34.4852w low $7.11
OCSSPY
Wall St. Highest PT $44.36 (+466.5%) Wall St. Avg PT $37.27 (+376.0%)
$7$21$34$47$61POC $28Hi $44Avg $37
Underwater Drawdown %Max DD -78.0%Current -76.0%
0.0%-78.0%
Relative Strength vs SPY-77.2% vs SPYUnderperforming
+92%0%-92%
1W
+$0.34 (4.54%)
1M
−$1.44 (15.53%)
3M
−$3.23 (29.17%)
6M
−$18.89 (70.70%)
YTD
−$12.14 (60.79%)
1Y
−$13.73 (63.67%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
10 analysts · mean score 1.30
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$7.83
Average target$37.27
+$29.44 (+376.0%) upsideaverage target vs current price
CurrentAverageMedian
Low$19.83
Median$37.27
High$44.36
12-month Wall Street target range
Recent analyst rating changes · 30
Reiterated
2026-09-18 · HC Wainwright & Co. reiterated Buy on OCS
Reiterated
2026-08-14 · JP Morgan reiterated Overweight on OCS
Reiterated
2026-08-05 · HC Wainwright & Co. reiterated Buy on OCS
Reiterated
2026-06-03 · JP Morgan reiterated Overweight on OCS
Reiterated
2026-06-02 · Baird reiterated Outperform on OCS
Reiterated
2026-06-01 · Stifel reiterated Buy on OCS
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$498.2M
P/E (next 12 months, estimated)-4.1
52-week range$7.11 – $34.48
Revenue growth (latest quarter vs a year ago)+18.8%
Dividend yieldNo dividend
Analyst consensusStrong Buy (10)
Average analyst price target$37.27 (+376%)

What they do

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for OCS yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

OCS earningsNext report in 6 days
Next report
Tue Nov 3, 2026Time not confirmed
EPS consensus-$0.40 range -$0.48–-$0.30
Revenue consensus$157.6K 9 analysts
Last 4 quarters · EPS vs estimate
Aug 6, 2026-$0.16est -$0.38+58.2%Above estimates
May 11, 2026-$0.49est -$0.41−19.8%Below estimates
Mar 3, 2026-$0.42est -$0.41−2.1%Below estimates
Nov 10, 2025-$0.32est -$0.41+22.2%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-22 20:15:01 ET
24-1125-0325-0525-0825-1126-0326-0526-08-0.690.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$0–
2026-03-31$0–
2025-12-31$0–
2025-09-30$0–
2025-06-30$0–

News & catalysts

More news
Oculis Reports New Phase 2 ACUITY Biomarker Data  Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis
GlobeNewswire · Oct 22
Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis
GlobeNewswire · Oct 22
Resolight Shares First Standard Support for Nanosecond OCS: Enabling a Step Change in AI Workload Economics
Business Wire · Oct 20
Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting
GlobeNewswire · Oct 20
Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting
GlobeNewswire · Oct 20
Rating changes
Reiterated
2026-09-18 · HC Wainwright & Co. reiterated Buy on OCS
Reiterated
2026-08-14 · JP Morgan reiterated Overweight on OCS
Reiterated
2026-08-05 · HC Wainwright & Co. reiterated Buy on OCS
Reiterated
2026-06-03 · JP Morgan reiterated Overweight on OCS
Reiterated
2026-06-02 · Baird reiterated Outperform on OCS
Reiterated
2026-06-01 · Stifel reiterated Buy on OCS

Third-party analyst actions, not SURVYR.'s views. All rating changes

Stats refreshed 2026-10-22 20:15:01 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026